Connect with us

Technology

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results

Published

1 hour ago

on

CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ — Cypherpunk Technologies Inc., (Nasdaq: CYPH) (“Cypherpunk”), today reported financial results for the second quarter ended June 30, 2026.

“In the second quarter, Cypherpunk built upon the momentum established earlier this year through the disciplined execution of our Zcash digital asset treasury strategy, increasing our treasury holdings to 323,394.38 ZEC, and welcoming Dev Ojha, founder of Valar Group, as an Advisor,” said Douglas E. Onsi, President and CEO of Cypherpunk Technologies. “Our Leap Therapeutics subsidiary reached alignment with the FDA on a proposed Phase 3 trial in a DKK1-high, second-line, metastatic colorectal cancer population, with objective response rate as the primary endpoint to support accelerated approval and overall survival to support full approval in the United States and registration globally. We are conducting a strategic process to determine the best path to advance sirexatamab, whether as an independently financed spin-out company or with a partner who shares our commitment to cancer patients.”

“In an increasingly AI-driven economy, the demand for true privacy is moving from a technical preference to a civilizational necessity. Our execution in the second quarter reinforces Cypherpunk’s conviction in Zcash as a foundational monetary asset. By growing our ZEC treasury, expanding our world-class advisory team, and continuing to back core infrastructure developers like ZODL, we are systematically positioning Cypherpunk to capture the long-term value of digital privacy adoption,” said Will McEvoy, Chief Investment Officer of Cypherpunk.

Cypherpunk Highlights:

Zcash treasury holdings increased to 323,394.38 ZECAs of August 11, 2026, Cypherpunk held a total of 323,394.38 ZEC at an average purchase price of $341.83, representing approximately 1.92% of the total circulating supply of the Zcash network.ZEC is a digital currency that can be transmitted over a peer-to-peer payment system. Zcash uses a cryptographic method called “zero-knowledge proofs” to allow users to engage in financial transactions while maintaining greater privacy.Dev Ojha Appointed as an AdvisorCypherpunk appointed Dev Ojha, the founder of Valar Group, a leading development and research team focused on the Zcash Network, as an Advisor. Valar Group has taken a significant role in developing Zakura, a high-performance full node software designed for massive scalability of Zcash, and on the Ironwood shielded pool. Dev also serves as an official ZIP Editor for Zcash protocol standards. Cypherpunk’s Advisory Team also includes: Arjun Khemani, Zcash key opinion leader; Josh Swihart, CEO of ZODL; Jeff Tiller, Chief of Staff of Gemini; and Zooko Wilcox, Founder of Zcash and Chief Product Officer at Shielded Labs.

Leap Therapeutics Subsidiary Highlights:

Publication of randomized Phase 2 DeFianCe study in Clinical Cancer Research Leap Therapeutics announced the publication of results from the randomized Phase 2 DeFianCe (NCT05480306) study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in Clinical Cancer Research. The publication, “Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial,” reported the complete efficacy, safety, and biomarker analyses from the study and details the statistical basis for the DKK1 biomarker finding.The peer-reviewed analyses establish that, while the prespecified primary endpoint was not met in the intent-to-treat population, the benefit of sirexatamab increases as a patient’s baseline plasma DKK1 level rises — a relationship confirmed by independent statistical approaches and reinforced by the observation that high DKK1 predicts poorer outcomes on standard of care alone. Together, these findings define DKK1-high metastatic colorectal cancer (mCRC) as a biologically distinct population with high unmet need.Reached FDA alignment on registrational Phase 3 trial in DKK1-high colorectal cancer Leap Therapeutics held a Type C meeting with the FDA to discuss the DeFianCe results and proposed registrational path for sirexatamab in DKK1-high, second-line mCRC. Leap presented its proposed Phase 3 trial design, and the FDA provided feedback supporting key elements of that design, including the use of a DKK1 biomarker-selected patient population and a dual-endpoint structure intended to support both accelerated and full approval.Leap Therapeutics reached alignment with the FDA on a randomized, controlled Phase 3 trial evaluating sirexatamab in combination with investigator’s-choice fluoropyrimidine-based chemotherapy (FOLFIRI or mFOLFOX6) plus bevacizumab, compared with chemotherapy and bevacizumab alone. Approximately 270 patients with mCRC whose disease has progressed following one prior line of systemic therapy prospectively identified as DKK1-high using a baseline plasma DKK1 assay cut point are expected to be enrolled and randomized 1:1. Potential accelerated approval in the United States could be determined by objective response rate (ORR) in an initial group of approximately 160 patients, and overall survival (OS) will be evaluated in the full study population intended to support a filing for full approval in the United States and to support registration in markets outside the United States.A blood-based companion diagnostic would be developed in parallel to identify DKK1-high patients in routine clinical practice.Sirexatamab received Fast Track designation from FDAIn May 2026, the FDA granted Fast Track designation to sirexatamab in combination with fluoropyrimidine plus oxaliplatin- or irinotecan-based chemotherapy and bevacizumab, for the treatment of patients with DKK1-high mCRC whose disease has progressed following one prior systemic therapy.The Fast Track program is intended to facilitate the development and expedite the review of drug candidates and vaccines that treat serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from frequent communication with the FDA, in addition to a rolling submission of the marketing application.Business updateLeap Therapeutics has initiated a strategic process to identify the best path forward for sirexatamab and to secure the resources required to advance the program into Phase 3 development. The process is expected to consider a range of alternatives, which may include financing the program as an independent entity, or a strategic transaction with a pharmaceutical or biotechnology company, including a partnership, license, collaboration, sale, or other business combination.There can be no assurance that the strategic process will result in any transaction or financing, or that any transaction or financing that is completed will be on terms favorable to the Company or its stockholders. The Company has not set a timetable for the conclusion of the process and does not intend to disclose developments unless and until it determines that further disclosure is appropriate or required.

Selected Second Quarter 2026 Financial Results

Net income was $39.4 million, or $0.18 per diluted share, for the second quarter of 2026, compared to a net loss of $16.6 million for the second quarter of 2025. The change was primarily due to a $46.0 million unrealized gain on the fair value of the Company’s ZEC treasury holdings during the second quarter of 2026, which are marked to market at the end of each period. During the second quarter of 2026, the price of ZEC increased from $243.35 to $400.09.

Research and development expenses were $0.2 million for the three months ended June 30, 2026, compared to $10.5 million for the same period in 2025. The decrease was primarily due to a decrease in clinical trial and manufacturing expenses due to the completion of the clinical trials, together with a decrease in payroll and related expenses associated with the 2025 reduction in force.

General and administrative expenses were $4.5 million for the three months ended June 30, 2026, compared to $1.8 million for the same period in 2025. The increase of $2.7 million for the three months ended June 30, 2026 was primarily due to a $1.7 million increase in stock-based compensation related to restricted stock units granted to general and administrative employees and directors in the fourth quarter of 2025, a $0.8 million increase in payroll and related expenses, and a $0.2 million increase in professional fees.

During the three months ended June 30, 2026, the Company recorded a $46.0 million unrealized gain on the change in fair value of the Company’s ZEC treasury holdings as the price of ZEC increased during the second quarter of 2026 from $243.35 to $400.09.

Cash and cash equivalents totaled $7.6 million on June 30, 2026, and ZEC treasury holdings, categorized as digital asset receivable, totaled $129.4 million based on the ZEC price of $400.09 on June 30, 2026.

About Cypherpunk

Cypherpunk Technologies is a privacy technology company. The Company’s mission is to advance technologies that guarantee privacy for humans on the internet. Cypherpunk pursues this mission through two primary strategies: accumulating Zcash (ZEC); and investing in, acquiring, and building technologies that push the frontier of privacy forward. Additionally, through its subsidiary Leap Therapeutics, the Company is developing novel therapies for patients with cancer, continuing the development of sirexatamab and FL-501. For more information about the Company, visit our websites at http://www.cypherpunk.com and http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov.

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. Forward-looking statements address various matters including statements relating to the value of the Company’s ZEC holdings, the investment in Zcash Open Development Labs (“ZODL”), or digital assets held or to be held by the Company, the expected future market, price, and liquidity of ZEC or other digital assets the Company acquires, the macro and political conditions surrounding Zcash or digital assets, the Company’s plan for value creation and strategic advantages, market size and growth opportunities, regulatory conditions, competitive position and the interest of other corporations in similar business strategies, technological and market trends, and future financial condition and performance. Risks and uncertainties of the digital asset treasury strategy include, among others: (a) risks relating to the Company’s operations and business, including the highly volatile nature of the price of ZEC; (b) the risk that material changes in the price of ZEC, such as decreases in price, will result in significant changes to the Company’s financial statements, such as unrealized losses on fair value of ZEC holdings and net loss; (c) the risk that the price of the Company’s common stock may be highly correlated to the price of ZEC; (d) the risk that the Company will fail to realize the anticipated benefits of the ZEC digital asset treasury strategy or the investment in ZODL; (e) risks related to the custody of our ZEC and our reliance on Gemini Space Station and its affiliates for trading and custody services; (f) changes in business, market, financial, political and regulatory conditions; (g) risks related to increased competition in the industries in which the Company does and will operate; (h) risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally; (i) risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and (j) the Company’s ability to comply with the continued listing requirements of the Nasdaq Capital Market.

With respect to our biotechnology operations, important factors that could cause actual results to differ materially from our plans, estimates or expectations could include, but are not limited to: (i) the DeFianCe study did not meet its prespecified primary endpoint of progression-free survival in the intent-to-treat population; (ii) the DKK1 biomarker subgroup and interaction analyses were exploratory, were based on a limited number of patients, were not adjusted for multiplicity, and may not be replicated in a prospective clinical trial; (iii) the impact of imbalances between treatment arms in the DKK1 subgroups; (iv) the risk that alignment with the FDA on trial design does not constitute agreement that any trial will succeed or that any marketing application will be accepted or approved, and the FDA may change its position at any time; (v) accelerated approval, if pursued, requires that the surrogate endpoint be reasonably likely to predict clinical benefit and is subject to confirmatory trial requirements and possible withdrawal if such requirements are not satisfied; (vi) the Company’s ability to initiate or complete the Phase 3 trial on the anticipated timeline or at all; (vii) the Company’s ability to obtain additional capital to advance sirexatamab on acceptable terms or at all; (viii) that risk that the strategic process may not result in any transaction or financing, may be terminated at any time, and any resulting transaction may not be on terms favorable to the Company or its stockholders; (ix) the Company’s ability to develop and validate a companion diagnostic; (x) the success of competing therapies; (xi) the Company’s ability to secure manufacturing capacity for sirexatamab; and (xii) the Company’s ability to maintain and protect its intellectual property rights.

New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. The Company may not actually achieve the forecasts disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC, or as may be included in other reports or information we file with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in its subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither the Company, nor any of its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

Cypherpunk Technologies Inc.

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

June 30, 

December 31, 

2026

2025

(Unaudited)

Assets

Current assets:

Cash and cash equivalents

$           7,624

$         14,035

Digital assets receivable

1,29,387

1,47,404

Research and development incentive receivable

–

602

Prepaid expenses and other current assets

539

40

Total current assets

1,37,550

1,62,081

Right of use assets, net

38

38

Deferred costs

348

401

Deposits

33

662

Other investment

5,000

–

Total assets

$       1,42,969

$       1,63,182

Liabilities and Stockholders’ Equity 

Current liabilities:

Accounts payable

$              588

$           1,981

Accrued expenses

1,014

2,067

Income tax payable

97

472

Lease liability 

38

38

Total current liabilities

1,737

4,558

Non-current liabilities:

Deferred tax liability

1,913

5,118

Total liabilities

3,650

9,676

Stockholders’ equity:

Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued
    and outstanding as of June 30, 2026 and December 31, 2025, respectively

–

–

Common stock, $0.001 par value; 490,000,000 shares authorized; 107,764,382 and 83,851,051
  shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively

108

84

Stock subscription receivable

–

(150)

Additional paid-in capital

6,39,618

6,16,216

Accumulated other comprehensive loss

(81)

(95)

Accumulated deficit 

(5,00,326)

(4,62,549)

Total stockholders’ equity 

1,39,319

1,53,506

Total liabilities and stockholders’ equity 

$       1,42,969

$       1,63,182

 

Cypherpunk Technologies Inc.
Consolidated Statements of Operations
(in thousands, except share and per share amounts)

 

(Unaudited)

(Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Operating expenses:

Research and development

$                  197

$             10,537

$                  358

$             23,448

General and administrative 

4,492

1,817

9,148

4,823

Restructuring charges

–

4,527

–

4,527

    Total operating expenses

4,689

16,881

9,506

32,798

Loss from operations

(4,689)

(16,881)

(9,506)

(32,798)

Interest income 

63

246

158

683

Interest expense

(6)

(7)

(13)

(13)

Australian research and development incentives

–

1

–

56

Change in fair value of embedded derivative

45,993

–

(31,562)

–

Foreign currency gain (loss)

1

(2)

1

(6)

Income (loss) before income taxes

41,362

(16,643)

(40,922)

(32,078)

Benefit from (provision for) income taxes

(1,973)

–

3,145

–

Net income (loss) attributable to common stockholders

$             39,389

$            (16,643)

$            (37,777)

$            (32,078)

Net income (loss) per share 

Basic 

$                 0.21

$               (0.40)

$               (0.21)

$               (0.78)

Diluted

$                 0.18

$               (0.40)

$               (0.21)

$               (0.78)

Weighted average common shares outstanding 

Basic

18,43,28,441

4,14,44,979

17,62,60,808

4,13,57,423

Diluted

21,73,43,013

4,14,44,979

17,62,60,808

4,13,57,423

 

 Leap Therapeutics, Inc. 
 Condensed Consolidated Statements of Cash Flows 
 (in thousands) 

 

 (Unaudited) 

 (Unaudited) 

 Three Months Ended June 30, 

 Six Months Ended June 30, 

2026

2025

2026

2025

 Cash used in operating activities 

$          (2,692)

$        (14,486)

$          (6,122)

$        (28,966)

 Cash used in investing activities 

(9,544)

–

(18,544)

–

 Cash provided by (used in) financing activities 

13,167

(119)

18,242

(180)

 Effect of exchange rate changes on cash and cash equivalents 

4

22

13

27

 Net increase (decrease) in cash and cash equivalents 

935

(14,583)

(6,411)

(29,119)

 Cash and cash equivalents at beginning of period 

6,689

32,713

14,035

47,249

 Cash and cash equivalents at end of period 

$           7,624

$          18,130

$           7,624

$          18,130

CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Cypherpunk Technologies Inc.
617-714-0360

For Investors:
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
leap@argotpartners.com

For Media:
Jacqueline Ortiz Ramsay
It Factor Strategies
954-294-3249
jacqueline@itfactorstrategies.com

 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/cypherpunk-technologies-reports-second-quarter-2026-financial-results-302849085.html

SOURCE Cypherpunk Technologies Inc.

Related Topics:
Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Cetera Welcomes Former Commonwealth Advisors Jim Tucker, Patrick Bria and Their Team Overseeing Approximately $420 Million in AUA

Published

23 minutes ago

on

August 12, 2026

By

After building their businesses over two decades, the advisors chose Cetera’s Summit community for its high-touch service, flexibility and commitment to helping advisors operate their way

SAN DIEGO, Aug. 12, 2026 /PRNewswire/ — Cetera welcomes financial advisors Jim Tucker, CFP®, CRPS®, and Patrick Bria, and the Tucker Bria Wealth Strategies team overseeing approximately $420 million in AUA1. Tucker Bria Wealth Strategies joined Cetera through its Summit Financial Networks2 community. Based in Durham, North Carolina, co-founders Tucker and Bria have built their practice together since 2013. The two have been friends since their teenage years in Pittsburgh, and later were teammates on Duke University’s varsity swim team.

Tucker Bria Wealth Strategies – a name built around the firm’s belief that “Life alters wealth®” – provides individualized financial planning and wealth management to individuals and families navigating life’s transitions, from wealth creation and preservation to windfalls such as inheritances and business sales.

The move to Cetera follows more than a decade at Commonwealth Financial Network, a firm Tucker and Bria deliberately chose for its culture of experienced advisors and personalized support. When LPL announced its acquisition of Commonwealth, the partners launched a monthslong search for a new financial services partner, including traditional broker-dealers and RIA models.

Keeping continuity for clients, some of whom have been with the practice since its inception, was central to their search. With Cetera, the firm could maintain its existing custodian, Fidelity’s NFS. Another key decision point was Cetera’s flexibility, which allowed Tucker Bria to continue using third-party technology that had become integral to their client service model during their years at Commonwealth.

Ultimately, the firm wanted access to a well-established and scaled infrastructure, products, services and AI-powered growth resources – tools designed to augment how advisors already work, not change how they operate – without asking the practice to give up how it runs its business.

“We were deliberate about choosing Commonwealth, and we were just as deliberate about where we went next. We wanted a partner strong enough to provide the compliance, technology and back-office support we didn’t want to build ourselves, but flexible enough to let us keep running our business exactly the way we always have,” Tucker said. “Summit has a clear reason for being, the same way our previous firm did, and that mattered to us as much as anything else.”

The firm’s high-touch approach to client service – centered on close, ongoing relationships rather than scale, with regularly scheduled client meetings and financial planning built around each family’s specific circumstances – was also at the forefront of their decision-making process.

“We tell our team to love our clients, not because of what they’ve entrusted to us, but because that’s simply the standard we hold ourselves to,” Bria said. “Our next-gen advisors are in the room with clients from day one, learning the relationships, not just the technical side of the job. Because of this, our clients know their advisor team is going to be in place for the next 30-plus years.”

Tucker Bria’s next generation – including Wealth Advisors Josh Polidori, CFP®, CPFA®; Financial Planning Associate Chris Bleeker; and Financial Planning Associate Taylor Clement, CFP® – already serves as the primary point of contact for many of the firm’s second- and third-generation clients.

Tucker is also the author of Family, Legacy, Wealth: How to Nurture and Grow Your Family Orchard, a book designed to help families define and pass on their legacy, one that goes beyond money.

Welcoming the Tucker Bria team, Cetera Advisor Channel Leader Tom Halloran said: “Jim and Pat have spent decades building something special together that grew into a client-centered practice with the kind of robust next-gen advisor strategy that doesn’t happen by accident. We’re thrilled to welcome Jim, Pat and their team to Cetera, and we’re eager to help them expand their legacy for many years to come.”

About Cetera

Cetera is the premier financial advisor Wealth Hub, empowering independent advisors and institutions with personalized support, flexible affiliation models, and end-to-end growth solutions. Home to approximately 12,000 financial professionals and institutions, Cetera’s multi-channel ecosystem enables financial professionals to grow, scale or transition their businesses on their own terms.

Unlike traditional IBDs, Cetera offers true choice – blending modern technology, integrated wealth solutions, and a community-driven culture. Cetera’s five-channel model and commitment to long-term advisor value provide a scalable blueprint for consistent, repeatable growth.

As of March 31, 2026, Cetera firms manage approximately $630 billion in assets under administration and $296 billion in assets under management. Its Voice of the Customer program has captured nearly 50,000 advisor reviews, with more than 43,000 five-star ratings, giving Cetera a 4.7 out of 5 satisfaction score.

Learn more at www.cetera.com and follow Cetera on LinkedIn, Instagram, Facebook, YouTube, and X.

Cetera is a network of independent retail firms, including those that are members of FINRA/SIPC: Cetera Advisors LLC; Cetera Wealth Services, LLC (formerly known as Cetera Advisor Networks); Cetera Investment Services LLC (marketed as Cetera Financial Institutions or Cetera Investors); and Cetera Financial Specialists LLC. Entities registered as investment advisers with the Securities and Exchange Commission include Cetera Investment Management LLC and Cetera Investment Advisers LLC. Cetera’s principal office is located at 655 W. Broadway, 11th Floor, San Diego, CA 92101.

Avantax Planning Partners, Inc., is an SEC registered investment adviser within the Aretec Group, Inc. (dba Cetera Holdings, an affiliate of CFG). All the referenced entities are under common ownership.

Cetera exclusively provides investment products and services through its representatives. Although Cetera does not provide tax or legal advice, or supervise tax, accounting or legal services, Cetera representatives may offer these services through their independent outside businesses. This information is not intended as tax or legal advice.

1Value approximated based on information provided to Cetera for asset holdings as of April 30, 2026.

2Summit Financial Networks is a region of Cetera Wealth Services, LLC. Securities offered through Cetera Wealth Services, LLC, member FINRA/SIPC. Advisory services offered through Cetera Investment Advisers LLC, a registered investment adviser. Cetera is under separate ownership from any other named entity.

View original content to download multimedia:https://www.prnewswire.com/news-releases/cetera-welcomes-former-commonwealth-advisors-jim-tucker-patrick-bria-and-their-team-overseeing-approximately-420-million-in-aua-302849021.html

SOURCE Cetera Financial Group

Continue Reading

Technology

Extra Space Storage CEO Joe Margolis Named One of Glassdoor’s Best CEOs of 2026

Published

23 minutes ago

on

August 12, 2026

By

SALT LAKE CITY, Aug. 12, 2026 /PRNewswire/ — Extra Space Storage Inc. (NYSE: EXR) today announced that CEO Joe Margolis has been named a 2026 Glassdoor Best CEOs Award recipient. The award recognizes chief executives whose leadership has earned high marks directly from employees.

Unlike many workplace honors, the Glassdoor award does not include a self-nomination process. Winners are determined solely through voluntary, anonymous reviews submitted by current and former employees. Margolis ranked No. 25 among the chief executives recognized, based on reviews submitted between May 16, 2025, and May 16, 2026. Additional details about the award methodology are available on Glassdoor’s awards website.

“This recognition belongs to our entire team and reflects the extraordinary culture we have built together at Extra Space,” Margolis said. “Every team member plays an important role in strengthening our culture and living our core values of Excellence, Teamwork, Innovation, Integrity and Passion. I am grateful to work alongside such talented people who make Extra Space an exceptional place to work and position us for a bright future.”

To learn more about working at Extra Space and explore current career opportunities, visit careers.extraspace.com. Extra Space has received multiple honors recognizing its workplace and company culture, see the full list here.

About Extra Space Storage Inc.

Extra Space Storage Inc., headquartered in Salt Lake City, Utah, is a self-administered and self-managed REIT and a member of the S&P 500. As of June 30, 2026, the Company owned and/or operated 4,410 self-storage stores in 42 states and Washington, D.C. The Company’s stores comprise approximately 3.0 million units and approximately 341.0 million square feet of rentable space operating under the Extra Space brand. The Company offers customers a wide selection of conveniently located and secure storage units across the country, including boat storage, RV storage and business storage. It is the largest operator of self-storage properties in the United States.

About Glassdoor

Glassdoor is transforming how people find jobs and companies they love by providing greater workplace transparency. Professionals use Glassdoor to research company ratings, reviews, salaries and more across millions of employers, and to participate in candid workplace conversations. Companies use Glassdoor to post jobs and attract talent through employer-branding and employee-insights products. Glassdoor is part of Indeed, a subsidiary of Recruit Holdings and a global leader in human resources technology and business solutions.

View original content to download multimedia:https://www.prnewswire.com/news-releases/extra-space-storage-ceo-joe-margolis-named-one-of-glassdoors-best-ceos-of-2026-302849387.html

SOURCE Extra Space Storage, Inc.

Continue Reading

Technology

FinThrive’s AI-Powered Fusion® Platform Earns Gold Stevie® Award for Healthcare Technology Innovation

Published

23 minutes ago

on

August 12, 2026

By

PLANO, Texas, Aug. 12, 2026 /PRNewswire/ — FinThrive, Inc., a leading healthcare revenue management software-as-a-service (SaaS) provider, today announced it has won a Gold Stevie® Award in the Technical Innovation of the Year – Hospitals & Health Systems category in the 2026 Stevie Awards for Technology Excellence.

The Stevie Awards for Technology Excellence celebrate the remarkable accomplishments of individuals, teams, and organizations shaping the future of technology across all industry sectors.

For more than 20 years, the Stevie Awards have been touted as the world’s premier business awards – the newest program sets a global benchmark for technology achievement.

The award recognizes FinThrive Fusion®, the company’s first‑of‑its‑kind AI‑powered data intelligence platform designed to unify and optimize the entire healthcare revenue cycle, enabling predictive insights, intelligent automation and autonomous workflows. By transforming disconnected healthcare data into intelligence, Fusion helps organizations prevent denials, billing errors and revenue leakage.

“Innovation matters only when it delivers meaningful outcomes for healthcare providers,” said Hemant Goel, President and CEO, FinThrive. “We’re honored that the Stevie Awards recognized FinThrive Fusion and our commitment to helping hospitals and health systems harness AI and connected data to strengthen financial performance, improve operational efficiency and better serve patients.”

Today, FinThrive supports healthcare organizations in all 50 states, processes more than 200 million claims annually and helps manage more than $1.4 trillion in healthcare revenue. Three out of five U.S. hospitals and health systems rely on FinThrive solutions to navigate today’s complex reimbursement environment.

More than 180 professionals worldwide participated in the judging process to select this year’s honorees.

About FinThrive 

FinThrive is a healthcare revenue cycle management (RCM) technology company that helps healthcare organizations maximize revenue, reduce costs and accelerate cash flow through a unified, intelligent platform. At the core is FinThrive Fusion, the industry’s first data intelligence platform built specifically for healthcare revenue operations. Powered by Fusion, FinThrive’s AI transforms complex, manual revenue cycle tasks into streamlined, autonomous workflows. It unifies data across the enterprise while supporting regulatory compliance. As one of the most advanced SaaS platforms in healthcare, FinThrive delivers a connected, holistic approach to revenue optimization. FinThrive’s solutions span patient access, charge integrity, claims and contract management, insurance discovery, automation, analytics and education, enabling organizations to manage performance across the front, middle and back office with greater visibility and control. Learn more at FinThrive.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/finthrives-ai-powered-fusion-platform-earns-gold-stevie-award-for-healthcare-technology-innovation-302849062.html

SOURCE FinThrive, Inc.

Continue Reading

Trending